‘It’s A Very Different Story,’ Pfizer CEO Bourla Says Of Cuts To Match COVID Revenue

 
• By Jessica Merrill

The company lowered Paxlovid and Comirnaty 2023 revenue projections by $9bn, announced plans for the commercial transition of the products, and revealed a cost-cutting plan.

cost cut
Pfizer announced a $3.5bn cost cutting program. • Source: Shutterstock

More from Strategy

More from Business